Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 620 participants.

Also called NCT07835581

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 620 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07835581
  • EU CT 2026-528156-15-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07835581. Randomized; no masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
Acronym
LEGACY
Condition
Kidney Transplant Rejection
Intervention (Drug)
Tegoprubart
Intervention (Drug)
Tacrolimus
Lead sponsor
Eledon Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07835581
Content hash
d9f6322b6bcb0226d2e665e22ca0b6e4d16204bb57b3d9d906dadc18af6a0a9a